Triple negative breast cancer
Drug research and approvals for triple negative breast cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 353 studies of triple negative breast cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 353
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Pucotenlimab and Anlotinib in Combination With ChemotherapyNCT07896668 · Phase 2 · Zhejiang Cancer Hospital · starts Sep 1, 2025
- Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative…NCT07880600 · Not reported · Fujian Cancer Hospital · starts Oct 8, 2026
- A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or…NCT07876557 · Phase 2 · Shanghai Junshi Bioscience Co., Ltd. · starts Oct 22, 2026
- Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerNCT07856225 · Not reported · Fundación Santa Fe de Bogota · starts Dec 1, 2025
- Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for…NCT07844473 · Not applicable · King Faisal Specialist Hospital & Research Center · starts Jul 24, 2026
- Role of Tumor Microbiota in the Response to Neoadjuvant Therapy in Patients Affected by Triple Negative Breast CancerNCT07808086 · Not reported · Istituti Clinici Scientifici Maugeri SpA · starts Sep 1, 2026
- A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid TumorsNCT07801508 · Phase 1 · Novartis Pharmaceuticals · starts Sep 8, 2026
- Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve…NCT07776951 · Not applicable · University of Milan · starts Feb 1, 2026
- Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC StudyNCT07773818 · Not reported · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · starts Aug 6, 2026
Approved 2
- AtezolizumabProgrammed cell death 1 ligand 1 inhibitor
- Sacituzumab govitecanTumor-associated calcium signal transducer 2 binding agent
Phase 3 12 of 18
- PaclitaxelTubulin inhibitor
- CarboplatinDNA inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- CapecitabineThymidylate synthase inhibitor
- CyclophosphamideDNA inhibitor
- CamrelizumabProgrammed cell death protein 1 antagonist
- EribulinTubulin inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- EpirubicinDNA inhibitor
- CisplatinDNA inhibitor
- VinorelbineTubulin inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
Phase 2 12 of 61
- DocetaxelTubulin inhibitor
- OlaparibPARP 1, 2 and 3 inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- RivoceranibVascular endothelial growth factor receptor 2 inhibitor
- PanitumumabEpidermal growth factor receptor erbB1 inhibitor
- EnzalutamideAndrogen Receptor antagonist
- BinimetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor
- RG-4733Gamma-secretase inhibitor
- TislelizumabProgrammed cell death protein 1 inhibitor
- AnastrozoleCytochrome P450 19A1 inhibitor
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
Phase 1 or earlier 12 of 37
- IrinotecanDNA topoisomerase I inhibitor
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- VistusertibSerine/threonine-protein kinase mTOR inhibitor
- Hiltonol
- ZEN-3694
- BexaroteneRetinoid X receptor agonist
- CelecoxibCyclooxygenase-2 inhibitor
- OxaliplatinDNA inhibitor
- TopotecanDNA topoisomerase I inhibitor
- VismodegibSmoothened homolog inhibitor
- RuxolitinibTyrosine-protein kinase JAK1 inhibitor
How its trials ended
920 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 216 whose ending is known, 24% met their primary endpoint, 7% missed it and 69% stopped early.
- Ongoing44949%
- Completed, result not reported15617%
- Status unknown9911%
- Stopped: other or unclear738%
- Met its primary endpoint526%
- Stopped: sponsor or business decision354%
- Stopped: enrollment or feasibility192%
- Stopped: lack of efficacy162%
- Missed its primary endpoint152%
- Stopped: funding51%
- Stopped: safety1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA